Author | Drug | Number of patients | Median response rate (%) | Median global survival (months) |
---|---|---|---|---|
Shoushtari [21] | Pembrolizumab | 35 | 23 | 12.4 |
D’angelo [22] | Nivolumab + Ipilimumab | 35 | 37.1 | Not reached |
Nivolumab | 86 | 23.3 | Not reached | |
Ipilimumab | 36 | 8.3 | Not reached | |
Yi [18] | Dacarbazine + Temozolomide | 21 | 26.3 | 9.2 |
Lian [20] | Cisplatin + Temozolomide | 30 | Not reported | 48.7 |
IFNα2b | 34 | Not reported | 40.4 | |
Harting [23] | IL2 | 11 | 36, partial response | 10 |
Guo [25] | Imatinib | 11 | 23 | 14 |